Critical Review: Aridis Pharmaceuticals (NASDAQ:ARDS) and Dogwood Therapeutics (NASDAQ:DWTX)

Aridis Pharmaceuticals (NASDAQ:ARDS) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Institutional and Insider Ownership

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aridis Pharmaceuticals and Dogwood Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Earnings & Valuation

This table compares Aridis Pharmaceuticals and Dogwood Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37 million	$0.31	0.00
Dogwood Therapeutics	N/A	N/A	-$34.26 million	($8.95)	-0.29

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Aridis Pharmaceuticals and Dogwood Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aridis Pharmaceuticals	0	0	0	0	0.00
Dogwood Therapeutics	1	0	1	0	2.00

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 365.12%. Given Dogwood Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Aridis Pharmaceuticals.

Risk & Volatility

Aridis Pharmaceuticals has a beta of 49.62, suggesting that its share price is 4,862% more volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Aridis Pharmaceuticals beats Dogwood Therapeutics on 8 of the 11 factors compared between the two stocks.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.